Novo Nordisk settles Minnesota insulin pricing case

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...